RxDoctor Payments Data

Brook Brouha, MD

Dermatopathology · la Jolla, CANPI 1114173937

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $17,029 of the $20,064 with a category attached, or 84.9%. It is spread thinly across 39 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Among dermatopathology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$20,064in general payments, 2019–2025

Across 911 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Arcutis Biotherapeutics, Inc.$3K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • Pfizer$1K
  • Sun Pharmaceutical Industries Inc.$1K
  • Incyte Corporation$1K
  • plus $9K from 33 others

What the payments were for

  • Consulting fees$2,25011%
  • Food & beverage$17,02985%
  • Education$7854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,064 in reported general payments places this provider in the 95th percentile of 76 dermatopathology providers in California.

See all dermatopathology providers in California

Medicare billing

Part B allowed, 2024
$398,799
Medicare patients
967
Services billed
15,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CibinqoAbrocitinib12$108,505
Dupixent PenDupilumab27$98,223
OpzeluraRuxolitinib Phosphate24$46,663
Dupixent SyringeDupilumab13$43,220
Clobetasol Propionate201$9,665
Ketoconazole203$3,071
Doxycycline Hyclate122$3,007
Tacrolimus17$2,357
Triamcinolone Acetonide169$1,831
Minoxidil183$1,732
Fluorouracil31$1,619
Betamethasone Dipropionate17$1,335
ValacyclovirValacyclovir Hcl32$1,189
Tretinoin13$985
Nystatin72$945

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerCibinqo$1,461$108,50512 claims
Incyte CorporationOpzelura$1,231$46,66324 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 76 dermatopathology providers in California.

Other dermatopathology in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →